Media coverage about Gemphire Therapeutics (NASDAQ:GEMP) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Gemphire Therapeutics earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.7441240749826 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

A number of brokerages have recently issued reports on GEMP. Piper Jaffray Companies restated an “overweight” rating and set a $22.00 price objective on shares of Gemphire Therapeutics in a research report on Friday, October 27th. Zacks Investment Research downgraded Gemphire Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 25th. HC Wainwright restated a “buy” rating and set a $22.00 price objective (up from $21.00) on shares of Gemphire Therapeutics in a research report on Tuesday, November 14th. Canaccord Genuity restated a “buy” rating and set a $31.00 price objective on shares of Gemphire Therapeutics in a research report on Monday, October 23rd. Finally, Roth Capital began coverage on Gemphire Therapeutics in a research report on Thursday, October 19th. They set a “buy” rating and a $30.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $22.17.

Shares of Gemphire Therapeutics (GEMP) opened at $8.13 on Monday. The company has a quick ratio of 4.17, a current ratio of 4.17 and a debt-to-equity ratio of 1.00. Gemphire Therapeutics has a one year low of $7.20 and a one year high of $21.59. The company has a market capitalization of $83.68, a P/E ratio of -2.41 and a beta of 2.92.

Gemphire Therapeutics (NASDAQ:GEMP) last announced its quarterly earnings data on Monday, November 13th. The company reported ($0.82) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.14). equities research analysts expect that Gemphire Therapeutics will post -3.31 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at

Gemphire Therapeutics Company Profile

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

Insider Buying and Selling by Quarter for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with's FREE daily email newsletter.